Clazakizumab (CSL300), our anti-interleukin-6 (IL6) monoclonal antibody, is currently being investigated in a Phase III clinical trial for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients. Vitaeris Bio now part of CSL BehringWhat are vitaeris and clazakizumab?
We’re proud to welcome Vitaeris and clazakizumab, an anti-IL-6 monoclonal antibody, currently in Phase III development for the potential treatment of chronic active antibody-mediated rejection (AMR).Where is Vita CSL based?
The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people, and delivers its life-saving therapies to people in more than 70 countries. For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring.